Improving outcomes for patients with diffuse large B-cell lymphoma

Christopher R. Flowers, Rajni Sinha, Julie Marie Vose

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL increased in both sexes, across racial categories, and across all age groups except the very young, the etiology of most cases remains unknown. DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Remarkable progress has been made in understanding the biological heterogeneity of DLBCL and in improving survival for DLBCL patients with novel combinations of chemotherapy and immunotherapy. Gene expression profiling (GEP) has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses, and the addition of the monoclonal antibody, rituximab, to CHOP has markedly improved outcomes. Future approaches to DLBCL management will use molecular signatures identified through GEP to provide prognostic information and to isolate therapeutic targets that are being evaluated for DLBCL patients who relapse or those with high risk disease.

Original languageEnglish (US)
Pages (from-to)393-408
Number of pages16
JournalCA Cancer Journal for Clinicians
Volume60
Issue number6
DOIs
StatePublished - Nov 1 2010

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Gene Expression Profiling
Combination Drug Therapy
Western World
Vincristine
Prednisone
Natural History
Non-Hodgkin's Lymphoma
Immunotherapy
Doxorubicin
Cyclophosphamide
Age Groups
Monoclonal Antibodies
Recurrence
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Improving outcomes for patients with diffuse large B-cell lymphoma. / Flowers, Christopher R.; Sinha, Rajni; Vose, Julie Marie.

In: CA Cancer Journal for Clinicians, Vol. 60, No. 6, 01.11.2010, p. 393-408.

Research output: Contribution to journalArticle

Flowers, Christopher R. ; Sinha, Rajni ; Vose, Julie Marie. / Improving outcomes for patients with diffuse large B-cell lymphoma. In: CA Cancer Journal for Clinicians. 2010 ; Vol. 60, No. 6. pp. 393-408.
@article{fa130b7f12ad4ca58357312621e4e0f3,
title = "Improving outcomes for patients with diffuse large B-cell lymphoma",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL increased in both sexes, across racial categories, and across all age groups except the very young, the etiology of most cases remains unknown. DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Remarkable progress has been made in understanding the biological heterogeneity of DLBCL and in improving survival for DLBCL patients with novel combinations of chemotherapy and immunotherapy. Gene expression profiling (GEP) has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses, and the addition of the monoclonal antibody, rituximab, to CHOP has markedly improved outcomes. Future approaches to DLBCL management will use molecular signatures identified through GEP to provide prognostic information and to isolate therapeutic targets that are being evaluated for DLBCL patients who relapse or those with high risk disease.",
author = "Flowers, {Christopher R.} and Rajni Sinha and Vose, {Julie Marie}",
year = "2010",
month = "11",
day = "1",
doi = "10.3322/caac.20087",
language = "English (US)",
volume = "60",
pages = "393--408",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Improving outcomes for patients with diffuse large B-cell lymphoma

AU - Flowers, Christopher R.

AU - Sinha, Rajni

AU - Vose, Julie Marie

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL increased in both sexes, across racial categories, and across all age groups except the very young, the etiology of most cases remains unknown. DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Remarkable progress has been made in understanding the biological heterogeneity of DLBCL and in improving survival for DLBCL patients with novel combinations of chemotherapy and immunotherapy. Gene expression profiling (GEP) has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses, and the addition of the monoclonal antibody, rituximab, to CHOP has markedly improved outcomes. Future approaches to DLBCL management will use molecular signatures identified through GEP to provide prognostic information and to isolate therapeutic targets that are being evaluated for DLBCL patients who relapse or those with high risk disease.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL increased in both sexes, across racial categories, and across all age groups except the very young, the etiology of most cases remains unknown. DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Remarkable progress has been made in understanding the biological heterogeneity of DLBCL and in improving survival for DLBCL patients with novel combinations of chemotherapy and immunotherapy. Gene expression profiling (GEP) has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses, and the addition of the monoclonal antibody, rituximab, to CHOP has markedly improved outcomes. Future approaches to DLBCL management will use molecular signatures identified through GEP to provide prognostic information and to isolate therapeutic targets that are being evaluated for DLBCL patients who relapse or those with high risk disease.

UR - http://www.scopus.com/inward/record.url?scp=78649391451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649391451&partnerID=8YFLogxK

U2 - 10.3322/caac.20087

DO - 10.3322/caac.20087

M3 - Article

C2 - 21030533

AN - SCOPUS:78649391451

VL - 60

SP - 393

EP - 408

JO - CA Cancer Journal for Clinicians

JF - CA Cancer Journal for Clinicians

SN - 0007-9235

IS - 6

ER -